Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes.

Diamant, Michaela; A Nauck, Michael; Shaginian, Rimma; K Malone, James; Cleall, Simon; Reaney, Matthew; de Vries, Danielle; J Hoogwerf, Byron; MacConell, Leigh; H R Wolffenbuttel, Bruce; Study Group, 4B

doi:10.2337/dc14-0876

Public

Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes.

Shared by NobleBlocks on Oct 1, 2014 • 12:00 AM UTC

Authors:

Michaela Diamant

Michael A Nauck

Rimma Shaginian

Abstract

OBJECTIVE: Mealtime insulin is commonly added to manage hyperglycemia in type 2 diabetes when basal insulin is insufficient. However, this complex regimen is associated with weight gain and hypoglycemia. This study compared the efficacy and safety of exenatide twice daily or mealtime insulin lispro ...

Discussions